PROM1 and neoplasm: To determine the impact of silencing/knocking-out LIS1 in CD133+ tumor cell population, the percentage of CD133+ cells in cancer cell lines transfected or edited at the genome level will be measured using flow cytometry and western blotting and compared with controls.